CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Plain-language summary
This trial is testing CD30-directed CAR-T cell therapy (patient's own T cells engineered to attack CD30 on lymphoma cells) for patients with anaplastic large cell lymphoma (ALCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 12 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
CAR T Cells (GENETIC): Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule: Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2.
CAR T Cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details